#nsclc
LightNews LightNews
stephenvliu.bsky.social
ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for #EGFR NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC. #LCSM

ascopubs.org/doi/10.1200/...
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights | JCO Oncology Practice
ascopubs.org
November 19, 2024 at 2:20 AM
sailorrooscout.bsky.social
So keep in mind, it’s approved for certain types of NSCLC but has not expanded to being approved for other types of cancer yet.
• www.fda.gov/drugs/resour...
• www.lungcancerresearchfoundation.org/subcutaneous...
August 24, 2026 at 5:29 PM
oncodaily.bsky.social
Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC - Hidehito Horinouchi
@hhorinouchi.bsky.social

oncodaily.com/insight/hide...

#AnnalsOfOncology #Cancer #EGFRMutated #NSCLC #Health #OncoDaily #Oncology #Osimertinib #Medicine #Telisotuzumab #Vedotin
Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC - OncoDaily
Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC / Annals of Oncology, cancer, EGFR-mutated NSCLC, Hidehito Horinouchi, NSCLC,
oncodaily.com
January 16, 2025 at 4:10 PM
oncodaily.bsky.social
FDA approval: Zenocutuzumab for NRG1+ NSCLC – IASLC

oncodaily.com/drugs/zenocu...

#ICYMI #Cancer #FDA #LungCancer #NRG1Fusion #NSCLC #OncoDaily #Oncology #Zenocutuzumab #Health #Medicine
FDA approval: Zenocutuzumab for NRG1+ NSCLC - IASLC - OncoDaily
FDA approval: Zenocutuzumab for NRG1+ NSCLC - IASLC / Alison Schram, cancer, FDA, ICYMI, Lung cancer, NRG1 fusion, NSCLC, OncoDaily, Oncology, Stephen V Liu,
oncodaily.com
January 23, 2025 at 9:54 PM
jinesh.bsky.social
Summary table of key trials in metastatic NSCLC
Table summarizing landmark trials in metastatic lung cancer
November 24, 2024 at 8:39 PM
oncodaily.bsky.social
The Babak Lab - A New Hope for ALK-Positive NSCLC Patients
@thebabaklab.bsky.social

oncodaily.com/insight/the-...

#Cancre #CancerResearch #LungCancer #NSCLC #CancerTreatment #Medicine #Health #Oncology #OncoDaily
A New Hope for ALK-Positive NSCLC Patients - The Babak Lab - OncoDaily
A New Hope for ALK-Positive NSCLC Patients - The Babak Lab / ALK-positive NSCLC, cancer, Ensacove, Ensartinib, OncoDaily, Oncology, The Babak Lab
oncodaily.com
March 4, 2025 at 9:44 PM
oncodaily.bsky.social
ADC Target Expression and Interstitial Lung Disease in NSCLC - Vivek Subbiah

https://oncodaily.com/insight/194410

viveksubbiah.bsky.social solangepeters.bsky.social

##Antibody ##AntibodyDrugConjugate ##Cancer ##InterstitialLungDisease ##Lungdisease ##NSCLC ##OncoDaily ##Oncology
Vivek Subbiah: ADC Target Expression and Interstitial Lung Disease in NSCLC - OncoDaily
Vivek Subbiah: ADC Target Expression and Interstitial Lung Disease in NSCLC / Aakash Desai, Ajay Sheshadri, antibody, antibody-drug conjugate, cancer,
oncodaily.com
December 3, 2024 at 11:00 AM
oncodaily.bsky.social
Prediction on the future of 1st line immunotherapy for NSCLC - Stephen Liu
@stephenvliu.bsky.social

oncodaily.com/blog/237621

#Cancer #FightAgainstCancer #GeorgetownUniversity #ITCD2025 #Ivonescimab #NSCLC #OncoDaily #Oncology #Medicine #Health
Stephen V Liu: Prediction on the future of 1st line immunotherapy for NSCLC - OncoDaily
Stephen V Liu: Prediction on the future of 1st line immunotherapy for NSCLC / cancer, fight against cancer, Georgetown University, Global fight against
oncodaily.com
February 4, 2025 at 4:53 PM
oncodaily.bsky.social
How active ADCs against oncogene-addicted NSCLC? - Giannis Mountzios
@drgreeklungcancer.bsky.social

oncodaily.com/blog/giannis...

#Cancer #CancerResearch #LungCancer #LCSM #NSCLC #Medicine #Health #Oncology #OncoDaily
Giannis Mountzios: How active ADCs against oncogene-addicted NSCLC? - OncoDaily
Giannis Mountzios: How active ADCs against oncogene-addicted NSCLC? / Alfredo Addeo, cancer, ESMO Treatment Reviews Journal, Giannis Mountzios, Jarushka
oncodaily.com
February 22, 2025 at 7:08 PM
drjnaidoo.bsky.social
#Gathering24
Superb 🇮🇪young investigator session at the Gathering in Cancer meeting, in Dublin today:

- ctDNA in NSCLC @davidoreilly.bsky.social #beaumontrcsi
- melanoma #SarahLochrin #mskcc
- GI cancer #TimOBrien
- oncogene+ NSCLC @drdavidmcmahon.bsky.social
- HCC #harryharvey

Well done all🏆
November 21, 2024 at 11:21 AM
oncodaily.bsky.social
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients

oncodaily.com/insight/259722

#Cancer #NSCLC #OncoDaily #Oncology #Medicine #Health #MedOnc #MedX #MedNews #MedEd
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients - OncoDaily
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients / cancer, Erick F. Saldanha, NSCLC, OncoDaily, Oncology
oncodaily.com
March 29, 2025 at 1:05 PM
jfc-already.bsky.social
Went out in the cold today didn't lose my breath.

Baby steps.

#NSCLC
#cansky
#ThanksCancer
February 9, 2025 at 3:05 PM
sharon43302.bsky.social
World’s first mRNA lung cancer vaccine, BNT116, developed by BioNTech, is in phase 1 human trials across seven countries, targeting non-small cell lung cancer (NSCLC). Using mRNA technology similar to COVID19 vaccines, it trains the immune system to attack cancer cells while sparing healthy tissue.
October 5, 2025 at 6:40 AM
rielymd.bsky.social
@pateloncology.bsky.social on his approach to immunotherapy in patients with NSCLC
November 15, 2024 at 8:25 PM
oncodaily.bsky.social
Hidehito Horinouchi Shares ASCO 2025 Abstract on Relatlimab Biology in Metastatic NSCLC
@hhorinouchi.bsky.social
@ascocancer.bsky.social

oncodaily.com/blog/asco-20...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASCO2025 #Relatlimab #NSCLC #LungCancer
Hidehito Horinouchi Shared ASCO 2025 Abstract on Relatlimab Biology in Metastatic NSCLC - OncoDaily
Hidehito Horinouchi Shared ASCO 2025 Abstract on Relatlimab Biology in Metastatic NSCLC / ASCO 2025, cancer, Hidehito Horinouchi, Lung cancer, NSCLC,
oncodaily.com
May 27, 2025 at 2:51 PM
oncodaily.bsky.social
Great discussions on antibody drug conjugates: including the future of ADCs in NSCLC - Stephen Liu
@stephenvliu.bsky.social

oncodaily.com/blog/stephen...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #ADCs
Stephen Liu: Great discussions on antibody drug conjugates - including the future of ADCs in NSCLC - OncoDaily
Stephen Liu: Great discussions on antibody drug conjugates - including the future of ADCs in NSCLC / Benjamin Levy, cancer, NSCLC, OncoDaily, Oncology, PRIME
oncodaily.com
April 26, 2025 at 9:04 PM
sailorrooscout.bsky.social
the tumor. What some may not know is that Amivantamab (brand name Rybrevant) used to treat certain types of advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations, was approved last December by the FDA to be given under the skin, which is called a subcutaneous (SQ)
August 24, 2026 at 5:27 PM
shelbytg.bsky.social
#canSky #OncSky #NSCLC #Lung #Cancer
lcrf.org Lung Cancer Research Foundation @lcrf.org · Mar 13
The House just passed a year-long continuing resolution (CR) that includes a devastating 57% cut to the Congressionally Directed Medical Research Programs (CDMRP), which would severely impact the Lung Cancer Research Program. Contact your senators: www.lungcan.org/act.
March 21, 2025 at 9:47 AM
oncodaily.bsky.social
ORACLE: A clonal-expression biomarker predicts stage I NSCLC outcome ⁦
@drjnaidoo.bsky.social

oncodaily.com/blog/223107

#Oncology #Medicine #OncoDaily #Cancer #Health
ORACLE: A clonal-expression biomarker predicts stage I NSCLC outcome ⁦ - OncoDaily
ORACLE: A clonal-expression biomarker predicts stage I NSCLC outcome ⁦ / Alexander M. Frankell, Allan Hackshaw, Aman Malhi, Amanda Lindberg, Balazs Dome,
oncodaily.com
January 14, 2025 at 2:55 PM
acmoorephd.bsky.social
All people with #NSCLC should get #biomarkertesting at diagnosis and at progression.
withfloyd.bsky.social L Floyd @withfloyd.bsky.social · Nov 19
I didn't understand until a year later the true importance of what she had done for me! Now I try to get the word out to all patients, especially in Canada where access is inconsistent.
November 19, 2024 at 12:39 AM
sanderlab.bsky.social
Vermutlich ist es ein "Klassen-Effekt" der mRNA-LNP Plattform. Diese führt zu einer Aktivierung des angeborenen Immunsystems, was sekundär CD8 T Zellantworten verstärkt. Der beobachtete Effekt war in Kombination mit einer Checkpunkt-Blockade (PDL1-Antikörper) bei NSCLC und Melanom.
October 22, 2025 at 8:56 PM
jfc-already.bsky.social
This shortness of breath and cough 15 days post thoracic surgery blows. I suppose it's better than the alternative. 😪

#ThanksCancer
#cansky
#lungcancer #NSCLC
February 7, 2025 at 5:30 PM
oncodaily.bsky.social
Positive Update from FLAURA2 Trial on EGFR NSCLC Treatment - Stephen V Liu
@stephenvliu.bsky.social

oncodaily.com/opinion/step...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FLAURA2 #EGFR #NSCLC
Stephen V Liu: Positive Update from FLAURA2 Trial on EGFR NSCLC Treatment - OncoDaily
Stephen V Liu: Positive Update from FLAURA2 Trial on EGFR NSCLC Treatment / cancer, EGFR+ NSCLC, NSCLC, OncoDaily, Oncology, Stephen V Liu
oncodaily.com
July 21, 2025 at 11:00 PM
oncodaily.bsky.social
The recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC – IASLC
@narjustflorezmd.bsky.social

oncodaily.com/blog/iaslc23...

#Cancer #FightAgainstCancer #GlobalAwareness #IASLC #LAURAtrial #LungCancerConsidered #NSCLC #OncoDaily #Oncology #Osimertinib
The recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC - IASLC - OncoDaily
The recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC - IASLC / cancer, fight against cancer, Global awareness, Global fight
oncodaily.com
February 7, 2025 at 4:48 PM
boghuma.bsky.social
mRNA vaccines are currently in development for the treatment of a variety of deadly cancers including:
Melanoma,Non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, head and neck cancers, etc.
March 17, 2025 at 9:29 AM